Patents by Inventor Raymond P. Warrell, Jr.

Raymond P. Warrell, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for Reducing Uric Acid Levels Using Barbiturate Derivatives
    Publication number: 20150133477
    Abstract: Methods for reducing uric acid levels in blood or serum of a subject employing metabolites of merbarone as active agents. Methods for treating or preventing disorders of uric acid metabolism are also provided. The metabolites can be formulated as pharmaceutical compositions comprising the metabolites and a pharmaceutically acceptable carrier for use in these methods.
    Type: Application
    Filed: November 13, 2013
    Publication date: May 14, 2015
    Inventor: Raymond P. Warrell, JR.
  • Taxane compounds, compositions and methods
    Patent number: 8785669
    Abstract: The present invention provides a method for the preparation of orally available pentacyclic taxane compounds, as well as intermediates useful in their preparation.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: July 22, 2014
    Assignee: GFV, LLC
    Inventors: John K. Thottathil, Raymond P. Warrell, Jr.
  • Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
    Patent number: 8273379
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: September 25, 2012
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Raymond P. Warrell, Jr., Pier Paolo Pandolfi, Janice L. Gabrilove
  • Taxane Compounds, Compositions And Methods
    Publication number: 20120004429
    Abstract: The present invention provides a method for the preparation of orally available pentacyclic taxane compounds, as well as intermediates useful in their preparation.
    Type: Application
    Filed: June 28, 2011
    Publication date: January 5, 2012
    Applicant: Genta Incorporated
    Inventors: John K. Thottathil, Raymond P. Warrell, JR.
  • PROCESS FOR PRODUCING ARSENIC TRIOXIDE FORMULATIONS AND METHODS FOR TREATING CANCER USING ARSENIC TRIOXIDE OR MELARSOPROL
    Publication number: 20110091573
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
    Type: Application
    Filed: December 21, 2010
    Publication date: April 21, 2011
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Raymond P. Warrell, JR., Pier Paolo Pandolfi, Janice L. Gabrilove
  • Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
    Patent number: 7879364
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
    Type: Grant
    Filed: September 30, 2005
    Date of Patent: February 1, 2011
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Raymond P. Warrell, Jr., Pier Paolo Pandolfi, Janice L. Gabrilove
  • Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
    Patent number: 7855183
    Abstract: The present invention is directed to the use of bcl-2 antisense oligomers to treat and prevent bcl-2 related disorders. These disorders include cancers, tumors, carcinomas and cell-proliferative related disorders. In one embodiment of the invention, a bcl-2 antisense oligomer is administered at high doses. The present invention is also directed to a method of preventing or treating a bcl-2 related disorder, in particular cancer, comprising administering a bcl-2 antisense oligomer for short periods of time. The present invention is further drawn to the use of bcl-2 antisense oligomers to increase the sensitivity of a subject to cancer therapeutics. The present invention also relates to pharmaceutical compositions comprising one or more bcl-2 antisense oligomers, which may comprise one or more cancer therapeutic agents.
    Type: Grant
    Filed: December 16, 2003
    Date of Patent: December 21, 2010
    Assignee: Genta Incorporated
    Inventor: Raymond P. Warrell, Jr.
  • Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
    Publication number: 20100216867
    Abstract: The present invention is directed to the use of bcl-2 antisense oligomers to treat and prevent bcl-2 related disorders. These disorders include cancers, tumors, carcinomas and cell-proliferative related disorders. In one embodiment of the invention, a bcl-2 antisense oligomer is administered at high doses. The present invention is also directed to a method of preventing or treating a bcl-2 related disorder, in particular cancer, comprising administering a bcl-2 antisense oligomer for short periods of time. The present invention is further drawn to the use of bcl-2 antisense oligomers to increase the sensitivity of a subject to cancer therapeutics. The present invention also relates to pharmaceutical compositions comprising one or more bcl-2 antisense oligomers, which may comprise one or more cancer therapeutic agents.
    Type: Application
    Filed: April 2, 2010
    Publication date: August 26, 2010
    Applicant: Genta Incorporated
    Inventors: Raymond P. Warrell, JR., Howard Fingert, Robert Klem
  • Pharmaceutical Gallium Compositions and Methods
    Publication number: 20090275655
    Abstract: The present invention provides novel pharmaceutical gallium compositions, as well as methods for their preparation and methods for treating conditions and diseases such as cancer, hypercalcemia, osteoporosis, osteopenia, Paget's disease, and infections.
    Type: Application
    Filed: April 28, 2009
    Publication date: November 5, 2009
    Applicant: Genta Incorporated
    Inventors: Raymond P. Warrell, JR., Bob D. Brown
  • Tri(alkylcarboxylato)gallium (III) products and pharmaceutical compositions containing them
    Patent number: 7119217
    Abstract: Provided are novel tri(alkylcarboxylato) gallium (III) compounds, exemplified by tripalmitato gallium (III), methods for making them, pharmaceutical compositions containing them, and methods of using the pharmaceutical compositions.
    Type: Grant
    Filed: September 22, 2003
    Date of Patent: October 10, 2006
    Assignee: Genta Incorporated
    Inventors: Jack B. Jiang, Raymond P. Warrell, Jr., Kollengode K. Ramaswamy, Robert E. Klem
  • Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
    Patent number: 6982096
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
    Type: Grant
    Filed: January 16, 2004
    Date of Patent: January 3, 2006
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Raymond P. Warrell, Jr., Pier Paolo Pandolfi, Janice L. Gabrilove
  • Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
    Patent number: 6884439
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
    Type: Grant
    Filed: January 16, 2004
    Date of Patent: April 26, 2005
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Raymond P. Warrell, Jr., Pier Paolo Pandolfi, Janice L. Gabrilove
  • Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
    Patent number: 6861076
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
    Type: Grant
    Filed: January 16, 2004
    Date of Patent: March 1, 2005
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Raymond P. Warrell, Jr., Pier Paolo Pandolfi, Janice L. Gabrilove
  • Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
    Patent number: 6855339
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
    Type: Grant
    Filed: January 16, 2004
    Date of Patent: February 15, 2005
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Raymond P. Warrell, Jr., Pier Paolo Pandolfi, Janice L. Gabrilove
  • Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
    Patent number: 6770304
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
    Type: Grant
    Filed: November 10, 1998
    Date of Patent: August 3, 2004
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Raymond P. Warrell, Jr., Pier Paolo Pandolfi, Janice L. Gabrilove
  • Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
    Patent number: 6723351
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
    Type: Grant
    Filed: April 30, 2003
    Date of Patent: April 20, 2004
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Raymond P. Warrell, Jr., Pier Paolo Pandolfi, Janice L. Gabrilove
  • Use of inhaled retinoids in the treatment of lung diseases
    Patent number: 6515022
    Abstract: Administration of retinoids by inhalation is used to overcome the chronic toxicity problems presented by systemic administration and to make retinoid therapy available as an option for the treatment of fibrotic lung disease, emphysema, and the prevention and treatment of epithelial cancers of the respiratory tract, especially those that are associated with tobacco use. Retinoids are administered by inhalation to the respiratory tract of the individual as an air-borne composition with a metered dose aerosol-producing inhaler, in which the retinoid is dissolved in a combination of a pharmaceutically acceptable chlorofluorocarbon propellant and an alkylamine solubilizing agent.
    Type: Grant
    Filed: May 11, 2001
    Date of Patent: February 4, 2003
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: William P. Tong, Raymond P. Warrell, Jr.
  • Transcription therapy for cancers
    Patent number: 6262116
    Abstract: The present invention provides method of treating a neoplastic condition in an individual, comprising the step of administering to said individual a pharmacologically effective dose of a retinoic acid and/or an inhibitor of histone deacetylase. Also provided is a pharmaceutical composition, comprising a retinoic acid, an inhibitor of histone deacetylase and a pharmaceutically acceptable carrier. Further provided is a method of inducing terminal differentiation of tumor cells in a tumor in an individual in need of such treatment, comprising the step of administering to said individual a pharmacologically effective dose of a retinoic acid and/or an inhibitor of histone deacetylase.
    Type: Grant
    Filed: September 18, 1998
    Date of Patent: July 17, 2001
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Pier Paolo Pandolfi, Raymond P. Warrell, Jr., Arthur Zelent
  • Methods for detection of acute promyelocytic leukemia (APL)
    Patent number: 5843642
    Abstract: The present invention provides a method of diagnosing APL in a subject which comprises detecting in a sample from the subject either nucleic acid encoding an abnormal RAR-.alpha. receptor or an expressed protein encoded thereby. The present invention also provides methods of identifying a subject with APL who will or will not respond to treatment with a retinoid, as well as a subjects with APL who do not express a detectable t(15;17) translocation but will or will not respond to treatment with a retinoid. In addition, the present invention provides methods for monitoring the activity of APL and the process of treatment of APL. The present invention provides methods of identifying a subject with a neoplastic condition other than APL who will or will not respond to treatment with a retinoid as well as methods for monitoring the level of disease activity and progress and adequacy of treatment of a neoplastic condition.
    Type: Grant
    Filed: July 21, 1993
    Date of Patent: December 1, 1998
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Ethan Dmitrovsky, Raymond P. Warrell, Jr., Wilson H. Miller, Jr., Stanley Frankel
  • Use of C-5 mono-substituted barbiturates to treat disorders of uric acid metabolism
    Patent number: 4880811
    Abstract: The present invention provides a method for decreasing the bodily content of uric acid in a subject which comprises administrating to the subject an effective content-decreasing amount of a barbiturate compound mono-substituted at the carbon-5 position.The invention also provides a pharmaceutical composition and a method for treating disorders of uric acid metabolism and resulting ailments in a subject.
    Type: Grant
    Filed: June 24, 1987
    Date of Patent: November 14, 1989
    Assignee: Memorial Hospital for Cancer and Allied Diseases
    Inventor: Raymond P. Warrell, Jr.